Yi Fan Pharmaceuticals: The company's innovative drug F-627 is expected to be directly shipped in the US mainland as soon as next year.

On September 25th local time, U.S. President Trump announced on his social media platform "Truth Social" that starting from October 1st, the United States will impose a 100% tariff on patented and branded drugs. In response, Yifan Pharmaceutical told reporters that the company's innovative drug F-627 was previously produced in the United States through CMO production and packaged and shipped in Germany. Recently, the company has been paying close attention to U.S. tariff policies and continuously optimizing the supply chain and cost solutions for F-627. They have already started the process of directly releasing and shipping the drug in the U.S. If the tariffs continue to be implemented and partners demand a sharing of the increased tariffs, it is expected that F-627 will be able to be shipped directly from the U.S. next year at the earliest. This policy does not have a significant impact on the sale of this drug in the U.S.